Apollo Hospitals Q4 FY26: Growth with disciplined execution across hospitals, retail health, and HealthCo

Apollo Hospitals Enterprise Limited closed Q4 FY26 with a familiar signature: steady hospital-led growth, sharp operating leverage, and improving profitability in the digital and pharmacy distribution stack. Consolidated revenue rose 18 percent year on year to ₹ 66,055 million. EBITDA increased 31 percent to ₹ 10,109 million, taking the EBITDA margin to 15.3 percent. Reported consolidated PAT grew 36 percent to ₹ 5,292 million, with PAT margin at 8.01 percent.

What makes this quarter stand out is not just the pace of growth, but the quality of it. Healthcare Services remained the anchor, expanding revenue 16 percent to ₹ 32,678 million with EBITDA margin at 23.9 percent. AHLL delivered a strong quarter with revenue up 24 percent to ₹ 4,895 million and EBITDA up 58 percent to ₹ 747 million, driven primarily by Diagnostics. Apollo HealthCo continued to scale its omnichannel model, with revenue up 20 percent to ₹ 28,482 million and a visibly improved profitability profile as digital losses narrowed.

The company also carried the cost of expansion. Four new hospitals commissioned in FY26 had pre-operative expenses or losses of ₹ 414 million in Q4 FY26. Even with this drag, established hospital units expanded margin meaningfully, highlighting how the mature network continues to subsidize and de-risk the ramp-up phase.

The quarter by business segment: hospitals lead, AHLL accelerates, HealthCo improves

Healthcare Services was once again the core engine. The hospital network reported 156,728 in-patients in Q4 FY26, up 7 percent year on year. The average revenue per inpatient rose 9 percent to ₹ 187,208, reflecting a mix of pricing and higher clinical intensity. Occupancy stood at 68 percent overall, with established units at 69 percent. Revenue growth was supported by volume, price, and case mix, and the company also cited strong performance in CONGO-T where volume grew 8 percent and revenue rose 18 percent in Q4 FY26.

Apollo Health and Lifestyle Limited, which houses Diagnostics and retail health formats, delivered one of its strongest quarters in recent periods. AHLL revenue grew 24 percent year on year and EBITDA grew 58 percent. Management attributed the outperformance primarily to Diagnostics, where quarterly revenue increased from ₹ 1,278 million to ₹ 1,939 million. In AHLL’s mix, Primary Care and Specialty Care also grew, but Diagnostics was the key driver of margin expansion.

Apollo HealthCo showed a cleaner story this quarter: scale continued and losses reduced. Total HealthCo EBITDA (post Ind AS) stood at ₹ 1,556 million, while the online digital EBITDA remained negative at ₹ (391) million, an improvement versus the prior year quarter’s ₹ (1,253) million. Digital cash loss for the quarter was ₹ 16 crores excluding ESOP charges, and the company highlighted sharper monetisation and disciplined discounting as contributors.

Hospitals: strong unit economics, with expansion costs visible but manageable

Apollo remains India’s largest pan-India hospital chain by network footprint, with 78 hospitals, capacity beds of 10,970 and operational census beds of 9,620. Owned hospitals account for 49 hospitals with 9,481 capacity beds and 8,131 operational census beds. The group also operates managed hospitals and a set of day surgery and Cradle facilities under AHLL.

In Q4 FY26, hospital EBITDA grew 14 percent to ₹ 7,806 million. Margin moderated slightly to 23.9 percent from 24.3 percent a year ago, but the more relevant indicator was the established unit margin, which expanded to 25.5 percent in Q4 FY26 from 24.4 percent in Q4 FY25. That gap reflects the cost of ramping new hospitals, a theme that continues into FY27 as newly commissioned beds are operationalized.

Operational metrics remained stable and supportive of profitability. ALOS declined to 3.19 days from 3.30 days, indicating faster throughput. Average revenue per inpatient increased 9 percent in the quarter and 10 percent for FY26, suggesting sustained pricing power and improved clinical mix.

The regional data shows Apollo’s typical pattern: metro markets deliver higher realizations while non-metros extend reach and broaden the catchment. For FY26 overall, metros reported ARPP per inpatient of ₹ 211,988 with occupancy of 70 percent, while non-metros reported ARPP of ₹ 128,352 with occupancy of 63 percent. The spread is large, and it underlines why Apollo’s expansion strategy tends to balance premium metro assets with tier-2 growth corridors.

Capital productivity also remained strong. Healthcare Services reported capital employed of ₹ 95,255 million with ROCE of 25.4 percent for FY26. The company also clarified that capital employed excludes CWIP of ₹ 10,324 million for new projects under development.

AHLL: Diagnostics drives margin expansion, retail health adds reach

AHLL is positioned as Apollo’s out-of-hospital care engine, spanning clinics, diagnostics, day surgery, and single-specialty formats such as dialysis and dental. The scale is already meaningful: 2,501 diagnostics centers, 316 clinics, 167 dialysis centers, and 280 dental centers as of Q4 FY26.

The Q4 performance showed a clear shift in profitability, especially within Diagnostics. Diagnostic EBITDA margin in Q4 FY26 was 14.1 percent versus 9.1 percent in Q4 FY25. The company also reported operational metrics that support the growth narrative: diagnostics footfalls per day were 23,908 in Q4 FY26 versus 14,898 in Q4 FY25, while gross average realization per patient was ₹ 787 compared to ₹ 822 a year earlier.

FY26 commentary suggests that growth was not limited to one pocket. Primary Care core revenues grew about 15 percent year on year, preventive health-checkup volumes rose about 28 percent, and the wellness segment grew about 34 percent and represented about 21 percent of Diagnostics revenue. AHLL also expanded its network, with a net addition of 10 satellite labs and 279 collection centers in FY26.

AHLL’s strategy is also being reshaped by corporate actions. The presentation notes a proposed combination of Apollo Cradle and Fertility Cloudnine, subject to CCI approval, aimed at creating one of India’s largest maternity and fertility care platforms. AHLL’s mother and child and fertility businesses were valued at INR 1,550 crores through a combination of cash and a 9.9 percent equity stake in the combined entity. If executed, this could streamline the specialty care portfolio while allowing AHLL to retain strategic upside.

Apollo HealthCo: omnichannel scale, narrowing digital losses, and a listing path

Apollo HealthCo sits at the intersection of offline pharmacy distribution and the Apollo 24/7 digital platform. The scale is clear: 7,289 operating stores as of March 31, 2026 and 47 million plus registered users on Apollo 24/7, with about 9 lakh daily active users.

The quarter’s message was operational discipline. Management pointed to leaner operations, higher per-order monetisation, and disciplined discounting. The company also highlighted the discontinuation of the Amazon partnership. Digital cash loss fell to ₹ 163 million in Q4 FY26, and the quarterly trend shows steady improvement from Q4 FY25’s ₹ (798) million to Q4 FY26’s ₹ (164) million.

Financially, the segment’s structure is now easier to read. Offline pharmacy distribution generated ₹ 25,184 million revenue in Q4 FY26 with EBITDA (pre 24/7 cost) of ₹ 1,947 million and margin of 7.7 percent. Online pharmacy distribution and Apollo 24/7 contributed ₹ 3,298 million revenue, with EBITDA (pre 24/7 cost) of ₹ 568 million and margin of 17.2 percent, but after allocating 24/7 operating cost of ₹ 732 million and ESOP charges of ₹ 227 million, online EBITDA remained negative at ₹ (391) million.

Over the full year, HealthCo revenue reached ₹ 108,081 million with EBITDA (post Ind AS) of ₹ 4,875 million and a margin of 4.5 percent, versus 1.8 percent in FY25. Reported PAT was ₹ 3,238 million for FY26.

Strategically, HealthCo is moving toward a new corporate structure. The board-approved composite scheme, announced earlier, is progressing, with NCLT directing a shareholders’ meeting on June 24, 2026. The scheme involves a demerger and amalgamation steps culminating in a New Co that becomes an Indian owned and controlled company and applies for listing. The presentation estimates listing by Q4 FY27 post approvals and highlights direct participation of AHEL shareholders in the resultant New Co.

Balance sheet and the investor lens: growth funded with control

For FY26, consolidated revenue was ₹ 252,285 million, up 16 percent. Consolidated EBITDA rose 25 percent to ₹ 37,693 million, and PAT grew 34 percent to ₹ 19,415 million. Net debt stood at ₹ 8,659 million, with consolidated gross debt at ₹ 32,015 million. Cash and cash equivalents included investments in liquid funds and fixed deposits of ₹ 15,242 million.

The expansion plan is large but staged. In FY26, Apollo commissioned four hospitals with 855 census beds, of which 185 beds were operationalized, leaving 670 beds to be operationalized over the next 12 to 18 months. The broader pipeline indicates a total project cost of ₹ 8,300 crores with about ₹ 5,100 crores remaining to be spent. The plan outlines expected commissioning of 835 census beds in FY27 and 1,970 census beds in FY29 to FY30, spanning Gurgaon, Sarjapur, Jubilee Hills, Secunderabad, Worli, OMR Chennai, Varanasi, Lucknow expansion, and a comprehensive cancer care plus proton facility in Hyderabad.

For investors, the key is whether ramp-up risk stays contained and whether mature unit economics remain intact. Q4 FY26 provides evidence on both. New hospitals are currently a visible drag, yet established units expanded margins. HealthCo’s loss reduction is also important because it reduces the need for cross-subsidies over time. Meanwhile, AHLL’s diagnostics-led margin improvement strengthens the out-of-hospital portfolio that is increasingly central to healthcare consumption.

Takeaways for investors

Apollo’s Q4 FY26 results show a company growing across all major legs of its platform, while still protecting unit-level profitability. Hospitals continue to compound with stable occupancy and higher realizations. AHLL is showing that diagnostics scale can translate into margin gains. HealthCo is moving in the right direction on digital losses while keeping offline pharmacy distribution healthy.

The near-term story is execution: ramping 670 commissioned beds, sustaining established unit margins, and continuing the digital loss trajectory. The medium-term story is structure: the proposed HealthCo scheme and the possibility of a listed New Co by Q4 FY27. If Apollo sustains this balance of growth and discipline, FY27 will likely be defined less by ambition and more by delivery.